Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Adding Bevacizumab to Erlotinib Prolongs PFS in EGFR-Mutated NSCLC

Wayne Kuznar
Published: Wednesday, Jun 06, 2018

lung cancer
The combination of bevacizumab (Avastin) and erlotinib (Tarceva) is superior to erlotinib alone as upfront treatment for non–small cell lung cancer (NSCLC) harboring EGFR mutations. A preplanned interim analysis of the phase III study known as NEJ026 showed a median progression-free survival (PFS) by independent review (the primary endpoint) of 16.9 months with the bevacizumab/erlotinib combination compared with 13.3 months with erlotinib by itself,1 said Naoki Furuya, MD, PhD, at the 2018 ASCO Annual Meeting.

The difference represents a 39.5% relative advantage on the primary endpoint favoring the combination (HR, 0.605; 95% CI, 0.417-0.877; P = 0.01573).

“The bevacizumab/erlotinib combination is considered a new standard therapy in patients with untreated EGFR-mutated NSCLC,” he said.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication